Rocket Pharmaceuticals Announces Participation at Upcoming Conferences
Sep 25, 2018
|
- Gaurav Shah, M.D., Chief Executive Officer, Invited as Panel Member
at The Galien Forum USA 2018 -
NEW YORK--(BUSINESS WIRE)--Sep. 25, 2018--
Rocket
Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading
U.S.-based multi-platform gene therapy company, today announced that
members of Rocket’s executive team will participate in the following
upcoming conferences:
-
Cantor Fitzgerald Global Healthcare Conference on October 1, 2018, at
9:30 a.m. Eastern Time in New York, NY
-
Ladenburg Thalmann 2018 Healthcare Conference on October 2, 2018, at
11:30 a.m. Eastern Time in New York, NY
-
Leerink Partners Roundtable Series: Rare Disease & Oncology on October
2, 2018, at 1:30 p.m. Eastern Time in New York, NY
-
Chardan Genetic Medicines Conference on October 9, 2018, at 2:00 p.m.
Eastern Time in New York, NY
-
Gene Therapy Panel during The Galien Forum USA 2018 on October 25,
2018, at 2:40 p.m. Eastern Time in New York, NY
A live audio webcast of the Ladenburg presentation will be available on
the Investors section of the company’s website, www.rocketpharma.com.
A replay of the presentation will be archived on the Rocket website
following the conference.
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is an emerging,
clinical-stage biotechnology company focused on developing
first-in-class gene therapy treatment options for rare, devastating
diseases. Rocket’s multi-platform development approach applies the
well-established lentiviral vector (LVV) and adeno-associated viral
vector (AAV) gene therapy platforms. Rocket's lead clinical program is a
LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a
difficult to treat genetic disease that leads to bone marrow failure and
potentially cancer. Preclinical studies of additional bone
marrow-derived disorders are ongoing and target Pyruvate Kinase
Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile
Malignant Osteopetrosis (IMO). Rocket is also developing an AAV-based
gene therapy program for an undisclosed rare pediatric disease. For more
information about Rocket, please visit www.rocketpharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180925005138/en/
Source: Rocket Pharmaceuticals, Inc.
Claudine Prowse, Ph.D.
SVP, Corporate Strategy and IRO
Rocket
Pharma, Inc.
The Empire State Building, Suite 7530
New York,
NY 10118
cp@rocketpharma.com
www.rocketpharma.com
investors@rocketpharma.com